Vivos Therapeutics Reports Full Year 2025 Financial Results
April 15, 2026 16:20 ET | Source: Vivos Therapeutics, Inc Full Year…
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates…
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative personalized off-the-shelf immunotherapy toward clinical development
April 14, 2026 03:30 ET | Source: Asgard Therapeutics Medical oncologist (ex…
AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company…
Pelthos Therapeutics Announces CFO Transition
Senior Vice President, Finance & Accounting John M. Gay named Chief Financial…
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
April 06, 2026 10:53 ET | Source: Celldex Therapeutics, Inc. HAMPTON, N.J.,…
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
April 02, 2026 08:00 ET | Source: Tvardi Therapeutics HOUSTON, April 02,…
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to…
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
